Trivalent seasonal influenza vaccine effectiveness during the 2015 season in South
Africa was assessed using a test-negative case control study design. Influenza A(H1N1) pdm09 was the dominant circulating strain. Overall influenza vaccine coverage was 3.2% (29/899). The vaccine effectiveness estimate, against any influenza virus infection, adjusted for age, underlying conditions and timing within season was 46.2% (95% CI: −23.5 to 76.5), and 53.6% (95% CI: −62.6 to 80.3) against influenza A(H1N1) pdm09.
K E Y W O R D S
effectiveness, influenza, vaccine
| INTRODUCTION
South Africa has a long-standing influenza sentinel surveillance system the Viral Watch which was started in 1984, to describe influenza seasonality and provide influenza strains for global vaccine strain selection. Sites are mainly general practitioners in the private healthcare setting, who submit the majority of specimens during the influenza season. Since 2005, it has also been used to estimate influenza vaccine effectiveness (VE). [1] [2] [3] [4] Recommendations for the use of influenza vaccine are published annually in South Africa. 
| METHODS
During 2015, 107 outpatient practitioners at 67 practices in eight of the nine provinces of South Africa participated in the Viral Watch sentinel influenza surveillance programme. Patients presenting with influenza-like illness (ILI) to participating practitioners and testing influenza virus-positive were defined as cases, whereas those who tested negative were used as controls. ILI was defined as acute respiratory illness with a measured temperature of ≥38°C or a history of fever, and cough, with onset within the past 10 days. Throat and/or nasal swabs were taken from a maximum of five patients per week, at the practitioner's discretion, as part of routine diagnostic investigations for which informed written consent was not required.
Specimens were tested using multiplex reverse transcription realtime polymerase chain reaction (rRT-PCR) assays for influenza A and B. Influenza A-positive specimens were further subtyped by rRT-PCR. 
| RESULTS
The Of the nine vaccinated influenza-positive patients, five were positive for influenza A(H1N1)pdm09, and two each for influenza A(H3N2) and influenza B.
Vaccine effectiveness estimates for all influenza adjusted for possible confounding factors showed timing within season to be the major confounder. (Table 3 ). ( Table 4) .
Vaccine effectiveness adjusted for underlying conditions and timing within seasons for adults aged 18 to 64 years for any influenza was 54.4% (95% CI: −14.1 to 81.8), 37.3% (95% CI: −93.6 to 77.7) against influenza A(H1N1)pdm09 and 28.2% (95% CI: −236.5 to 84.7) against influenza B. When restricted to specimens collected within 3 days of onset, or when the type or subtype was circulating, a decrease in VE was shown in both occasions for influenza A(H1N1)pdm09. None of the cases positive for influenza A(H3N2) in this age group had received vaccine. (Table 5 ). 9 Early VE against medically attended laboratory-confirmed influenza for the first 10 weeks of the season in Europe was reported to be 46% with a predominance of influenza A(H1N1)pdm09.
| DISCUSSION

10
Although persons aged ≥65 years had the highest vaccine coverage, we were unable to show VE in this age group due to the small sample size. Previous studies have shown that although antibody response and protection elicited by influenza vaccination are lower amongst the elderly, influenza vaccination in this group is still associated with reductions in the rates of hospitalisation and death. 11, 12 In addition, the percentage increase in winter deaths attributable to influenza was substantially higher in South African elderly as compared to the United States.
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There are several limitations to our study especially the low vaccine coverage which affected the ability to statistically estimate significance of VE amongst subgroups such as individuals >65 years of age. Although the VE point estimates varied when analysed restricted by time of specimen collection after onset, or weeks when the type or subtype was circulating and none were statistically significant, we cannot exclude the potential of residual confounding. In addition, Viral Watch patients are unlikely to be a random sample, and the vast majority are patients accessing private health care, whereas only about 20% of the South African population have private healthcare insurance; however, they are also the group with highest influenza vaccine coverage. Influenza vaccination status and underlying conditions were self-reported by some patients to the practitioner, which could have led to misclassification.
| CONCLUSION
Despite low influenza vaccine coverage in South Africa, we were able to estimate VE. Late arrival of the vaccine may have contributed to limiting the number of patients protected against influenza during the season. Influenza vaccine had moderate effectiveness in our setting in 2015.
